The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Weight loss of 5% or greater was achieved by 79.2% of patients on semaglutide 25mg vs 31.1% of those on placebo (P <.0001). Semaglutide-treated patients also saw significant improvements in ...

In a significant medical breakthrough, the widely used weight loss ... 22.4% in the placebo group. These numbers suggest that semaglutide may do more than support weight loss — it may actually ...

The key ingredient in blockbuster weight-loss drugs could ... of patients who took semaglutide once per week saw improvements on both inflammation and scarring in the liver, compared with about 16 per ...

which studied 25 milligram dose of oral semaglutide compared to placebo in 307 adults with obesity with one or more comorbidities. The company is also studying weight-loss pill amycretin ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide ... placebo. Among those who adhered to treatment, the high-dose group achieved an average weight loss ...

The median percentage of total body weight loss in the placebo + semaglutide group that was due to lean mass was 32% and estimated fat loss was 68%. In contrast, in the all enobosarm + semaglutide ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE ...

versus 22.4% in the placebo group. Participants treated with semaglutide also saw improvements in liver enzymes and blood measures of liver fibrosis, as well as 10.5% weight loss. Some adverse ...